06 August 2018
Visiongain’ has launched a new pharma report Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market : Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs
This report is intended to provide an in-depth analysis of the latest trends of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market and its growth and development in the next decade. The changing demographics of the world population, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.
This report examines in detail the market forecast by geography, by mechanism of action, as well as by innovator & off-label drugs during 2017-2027, providing the reader with a thorough overview of the market to identify key growth areas and business opportunities.
The lead analyst of the report commented “The global anti-idiopathic pulmonary fibrosis drugs market is driven by the rising prevalence and incidence of IPF patients, expected launch of novel therapies, special regulatory (Orphan and Fast-track) designations for pipeline molecules, increased understanding of disease pathogenesis, and limited number of current players.
However, the growth of this market might be slowed down by various challenges during the forecast period with use of off-label drugs, availability of non-pharmacological therapies, and lack of proper diagnosis techniques as well as the absence of highly efficacious & safe drugs.”
Leading companies featured in the report include Actelion, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen, Galapagos, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, Kadmon Pharmaceuticals, LTT, Bio-Pharma, MediciNova, Merck, Moerae, Pacific Therapeutics, Promedior, ProMetic Life Sciences, Roche, Sanofi, Teva, Zai Lab
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.